Latest News and Press Releases

CHESTERBROOK, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

CHESTERBROOK, Pa., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

CHESTERBROOK, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a...

No dose adjustments required for patients with renal impairment or patients with mild / moderate hepatic impairment CHESTERBROOK, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:...

Safety and tolerability demonstrated in diverse patient populations and surgeries CHESTERBROOK, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company...

CHESTERBROOK, Pa., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

Company expects to resubmit NDA for oliceridine in Q1 2020  Acute migraine proof-of-concept study for TRV250 initiated  Company to host conference call at 8:30 a.m. EST CHESTERBROOK, Pa., Nov. 04,...

CHESTERBROOK, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

CHESTERBROOK, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...